Meeting
2023 ASCO Annual Meeting
Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.
Authors
Michael C. Heinrich
Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, OR
Michael C. Heinrich , Jian Li , Xinhua Zhang , Robin L Jones , Suzanne George , Jonathan C. Trent , Cesar Serrano , Yanhong Deng , Sebastian Bauer , Shirong Cai , Xin Wu , Yongjian Zhou , Kaixiong Tao , Zhichao Zheng , Jun Zhang , Yuehong Cui , Hui Cao , Meining Wang , Jin Hu , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT02508532, NCT04254939
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11523)
DOI
10.1200/JCO.2023.41.16_suppl.11523
Abstract #
11523
Poster Bd #
457
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2020 Gastrointestinal Cancers Symposium
Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).
First Author: Michael C. Heinrich
Poster
2016 ASCO Annual Meeting
Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).
First Author: Yemarshet Kelemework Gebreyohannes
Poster
2023 ASCO Annual Meeting
Combination targeted therapy with avapritinib and sunitinib in patients with refractory gastrointestinal stromal tumors after failure of standard treatments: A small prospective pilot study.
First Author: Yanzhe Xia